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Abstract: Introduction: Studying the treatment effect of subclinical hypothyroidism in decreasing metabolic syndrome
risk factors and cardiovascular diseases is necessary and can be helpful to control future disorders. In spite of
various studies, the relationship between subclinical hypothyroidism and cardiovascular diseases remain con-
troversial. Studies which consider the effects of subclinical hypothyroidism treatment on metabolic control and
insulin resistance have not been done in the Islamic Republic of Iran yet. Materials and methods: In this inter-
ventional study, 153 patients with subclinical hypothyroidism (thyroid stimulation hormone (TSH) >5, normal
T3 and T4 at least 2 times) were selected from Labbafinejad endocrine clinic. Laboratory tests were performed
at 8 a.m. after 12-14 hours fasting. Patients were then treated with levothyroxine (25-50 µg daily). To adjust
the dose, thyroid function tests (TFT) were checked every 2 months for 6 months. Collected data was used
for analysis by spss18 software. Results: After 6 months treatment of subclinical hypothyroidism mean values
improved in factors such as insulin resistance profile (fasting blood sugar (FBS), 2 hours post prandial (2hPP),
fasting insulin and homeostasis model assessment estimated insulin resistance (HOMA-IR index), lipid profile
(total cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL), decreased c-reactive pro-
tein (CRP) and weight (all had P value<0.05). Treatment did not have significant effect on triglycerides (TG),
waist circumference, body mass index (BMI), uric acid ad systolic/diastolic blood pressure (p values>0.05). But
the number of cases with high systolic/diastolic blood pressure decreased significantly after 6 months treat-
ment (P values=0.007 and 0.01). Conclusion: Subclinical hypothyroidism treatment is suggested according to
mentioned effects, especially in cases with insulin resistance, lipid profile disturbance, obesity, and high blood
pressure.
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1. Introduction
hypothyroidism is one the most common thyroid dysfunc-
tions and has two types: subclinical hypothyroidism (SHT)
and overt hypothyroidism(1-4)Subclinical hypothyroidism is
characterized by high serum TSH and normal free T3 (FT3)
and free T4 (FT4). (1, 5, 6) Prevalence of subclinical hypothy-
roidism is %3-8 in euthyroid population, it increases with age
and is more common in women although after the age of 50
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jmp.iums.ac.ir
K. Roohigilani et al. 2
it becomes the same in men and women and the total preva-
lence increases to %10. (7)
Subclinical Hypothyroidism can lead to overt hypothy-
roidism and increase the risk of coronary artery disease
(CAD) and other cardiovascular diseases as well as osteo-
porosis, change in mineral elements, anemia, depression
and memory dysfunction.(2, 5, 8)Dyslipidemia and insulin
resistance in patients with subclinical hypothyroidism has
been reported in different studies.(2, 8-10) No correlations
between serum TSH, BMI, and lipid profile has been proved
in various studies.(10-13) There are no sufficient information
about metabolic state and insulin resistance in patients with
subclinical hypothyroidism.
Although there are various studies considering adverse ef-
fects of Subclinical hypothyroidism there are no agreement
about clinical importance and profits of levothyroxine treat-
ment especially in those %80 patients with TSH<10 mIU/L,
because different TSH and SHT levels are not considered in
these studies.(9, 14) The clinical importance of therapy for
mild elevation of serum TSH (<10 mIU/L) (6, 15) and the ex-
act upper limit of normal for the serum TSH level remain
subjects of debate(6, 16-19). When the TSH level is above
10 mIU/L, levothyroxine therapy is generally agreed to be ap-
propriate(6, 15, 20). However, management of patients with a
serum TSH level of less than 10 mIU/L is controversial. (6, 14)
Studying the treatment effect of subclinical hypothyroidism
in decreasing metabolic syndrome risk factors and cardiovas-
cular diseases is necessary and can be helpful to control fu-
ture disorders. In spite of various studies, the relationship
between subclinical hypothyroidism and cardiovascular dis-
eases remain controversial. We assessed the effects of thyroid
hormone replacement on metabolic control and insulin re-
sistance in patients with subclinical hypothyroidism referred
to Labbafinejad hospital endocrine clinic during 2010.
2. Materials and Methods
2.1. Study design
This Before and After Interventional Study included 159 sub-
clinical hypothyroidism (TSH>5, normal T3 and T4) patients.
Inclusion criteria of the study included men and women pre-
sented to the endocrinology clinic of Imam Hossein Hos-
pital with the finding of an elevated TSH and normal FT4
and T3 level indicating new diagnosis of subclinical hypothy-
roidism. Exclusion criteria of the study included patients un-
der treatment with levothyroxine for the past 3 months or
lipid-reducing drugs for the past 6 months, any past medi-
cal history of CAD, DM, pituitary or hypothalamus disorders
and any other disorders effecting lipid metabolism. Patients’
serums were collected at 8 a.m. after 12-14 hours overnight
fasting and was checked for lipid profile, TSH, T4, T3, serum
insulin level, CRP, FBS, uric acid and 2-hour postprandial glu-
cose after breakfast. Then height, weight, BMI and blood
pressure of the patients were measured, and patients under-
gone treatment with levothyroxine 25-50 micrograms daily.
All patients were recommended to maintain their usual ex-
ercise and diet habits. Levothyroxine dose was determined
after checking TSH and T4 every 2 months. Eventually after 6
months the initial laboratory tests were repeated and evalu-
ated and the results were imported to SPSS 18 for analysis.
2.2. Patients
Subjects of this study were patients referring to Labbafinejad
hospital endocrine clinic with subclinical hypothyroidism
that had 2 consecutive tests showing TSH>5mIU/L and nor-
mal T3 and T4. Patients should not have been under treat-
ment with levothyroxine for the past 3 months or lipid-
reducing drugs for the past 6 months and shouldn’t have had
history of CAD, DM, pituitary or hypothalamus disorders and
any other disorders effecting lipid metabolism.
2.3. Statistical analysis
Data collection method of this study is Non Probable & Con-
venience, volume of the samples was calculated 144 patients
which considering %10 probable loss will come to 159 pa-
tients, after completing the study 153 patients remained until
the end. Collected data was analyzed descriptively by mea-
sures of central tendency and then qualitative variables were
analyzed trough ANOVA and Chi2 tests and quantitative vari-
ables were analyzed trough paired t-test (α=0.05, β=0.2).
2.4. Ethical considerations
Due to Helsinki convention, name and personal information
of the patients will remain confidential with the researchers
and all reports will be generalized and nameless. All patients
were given written consent forms to participate in the study
and they were handed sufficient information about the study.
3. Results
In this interventional study 159 patients passed the entering
criteria but only 153 patients remained until the end of study
and the collected data from them was analyzed. These pa-
tients had an average age of 41.29 (SD=14.9), ages varied from
19-70 years old. 51 patients (%33.3) were men and 102 pa-
tients (%66.7) were women. Other factors such as TSH, T4,
T3, CRP, fasting serum insulin, FBS, 2hPP, HOMA score, to-
tal cholesterol, LDL, HDL, and body weight had a significant
difference before and after treatment also the number of pa-
tients with high systolic or diastolic pressure dropped clearly.
On the other hand, treatment did not seem to have a signif-
icant effect on serum TG, BMI, waist circumference, mean
diastolic or systolic blood pressure and uric acid. (Table 1)
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4. Discussion
This is a before and after interventional study with 153 pa-
tients and %66.7 of them are women which is acceptable con-
sidering the higher prevalence in women.
4.1. Thyroid profile and inflammation
T3 and T4 levels both shown significant increase after treat-
ment (table1). TSH levels had significant decrease after treat-
ment (table1) which is the same result Ganie and associates
(21) achieved in their studies, showing proper and adequate
treatment in our patients. CRP decreased significantly after
treatment (table1), studies done by Al Sayed (22) and Sharma
(23) reported higher levels of CRP in SHT patients. Therefore,
it seems that treatment of SHT can decrease CRP levels and
treat chronic inflammations.
4.2. Blood sugar and insulin resistance
This study shows significant decrease in fasting serum in-
sulin, FBS, 2hPP and HOMA score (Table1), in Al Sayed (22)
study, fasting serum insulin was higher in SHT patients but
there was no significant difference in HOMA score between
SHT patients and control group so the numbers are quite
similar but there is a disagreement between the studies of Al
sayed(22), Dessein (24), Singh (25) and others (26, 27) which
show that SHT can lead to or exacerbate insulin resistance,
and studies of Ganie(21), Liu(28), Oweeki(29) and others(22,
27, 30) which indicate SHT does not have any relations with
insulin resistance. Therefore, according to the findings in this
study SHT treatment can decrease insulin resistance indexes.
4.3. Lipid profile
In our study LDL and total cholesterol decreased significantly
and HDL showed a significant increase, TG in the other hand
did not vary significantly. (Table1) Similarly in articles pub-
lished by Al Sayed (22), Dessini (24), Ganie (21), Sharma
(23), Iqbal (30)and Razvi (31), total cholesterol and LDL were
higher in SHT patients than control group. Al sayed (22) and
Kong (32) reported no statistical difference in HDL. Therefor
according to our study and the others mentioned treatment
of SHT improves lipid profile by effecting cholesterols but has
no effect on TG.
4.4. Body indexes
This study shows significant decrease in body weight but no
statistical difference in BMI and waist circumference after
treatment. (Table1) Al Sayed (22) studies show higher weight
in SHT patients than control group. In Razvi (31) and Lu-
boshitzky (33) studies SHT patients had higher waist circum-
ference and it is indicated that treatment of SHT can signifi-
cantly decrease waist circumference. Overall, this study and
the others show that treatment of SHT can lead to weight loss
but has no significant effect on BMI, also waist circumference
can be lowered trough the treatment but this has not been
shown by this study.
4.5. Blood pressure
According to this study SHT treatment has no significant ef-
fect on average SBP or DBP (table1), Ganie (21) studies also
indicates this. Article published by Erkan (34) F on the other
hand shows that treatment could lead to decrease in blood
pressure. Overall, this study shows no effect of the treatment
on average blood pressure but can significantly decrease the
quantity of those patients with high SBP or DBP.
There were some limitations to this study including the poor
cooperation of patients and discontinuing the treatment for
resolving this problem %10 more patients were added to the
study. Generalization to all the patients cannot be concluded
and cannot be resolved with available facilities.
5. Conclusion
Considering this study and the similar published studies 6
months treatment of SHT can improve lipid and insulin re-
sistance profile and decrease in CRP and body weight but
has no effect on TG, waist circumference, BMI, uric acid, and
blood pressure, it can however help patients with high SBP
and DBP. According to these benefits, therefore, treatment is
suggested especially in patients with insulin resistance, dys-
lipidemia, obesity and systolic or diastolic hypertension.
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Table 1: Test results in patients before and after treatment with levothyroxine.
Factor Mean value before
treatment (SD)





TSH mIU/L 9.95±(2.96) 2.97±(2.21) 5.2 (0.2) 15.8 (5) <0.001
T4 µg/dl 6.83±(1.22) 8.85±(1.46) 4.4 (6.3) 9.3 (12.2) <0.001
T3 µg/dl 0.8±(0.29) 1.36±(0.53) 0.2 (0.3) 1.55 (2.5) <0.001
CRP mg/l 4.04±(3.63) 2.95±(2.67) 1.2 (0.1) 14.7 (10.7) 0.03
Fasting serum insulin
mIU/L
10.52±(3.06) 7.92±(3.03) 2.5 (1.5) 15.8 (15.5) 0.035
FBS mg/dl 97.6±(10.96) 93.54±(10.17) 74 (67) 125 (111) <0.001
2hPP mg/dl 110.63±(24.69) 95.88±(16.67) 72 (66) 167 (136) 0.018
HOMA score 2.42± (2.6) 1.93± (0.78) 0.67 (0.46) 4.14 (3.7) <0.001
TG mg/dl 117.52±(48.39) 119.3±(41.26) 50 (43) 223 (190) 0.45
Total cholesterol mg/dl 195.64±(37.3) 186.97±(29.66) 143 (137) 296 (254) 0.015
LDL mg/dl 119.5±(23.9) 103.4±(19.4) 82 (57) 180 (137) <0.001
HDL mg/dl 47.19±(12.11) 53.64±(16.38) 26 (33) 74 (95) 0.04
Body weight kg 73.19±(9.11) 71.08±(9.12) 52 (51) 97 (96) 0.047
BMI kg/m2 27.1±(2.66) 26.3±(2.7) 20.7 (20.3) 30.4 (30) 0.56
Waist circumference
cm
98.9±(7.4) 98.3±(7.6) 81 (80) 115 (115) 0.09
Systolic BP mmHg 126.12±(16.4) 115.01±(13.3) 92 (92) 167 (147) 0.81
Patients with SBP >
140mmHg
23 8 - - 0.007
Diastolic BP > 90mmHg 78.34±(8.3) 71.6±(10.22) 62 (42) 97 (87) 0.88
Patients with DBP 11 0 - - 0.01
Uric acid mg/dl 6.48±(1.81) 5.7±(1.9) 3.2 (1.5) 10.4 (9.3) 0.053
Table 2: Baseline characteristics.
Characteristics Total participants Men Women Mean age (SD) Minimum age Maximum age
Value 153 51(%33.3) 102(%66.7) 41.29± (14.9) 19 70
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